Bafna Pharmaceuticals Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Bafna Pharmaceuticals' board has approved the unaudited financial results for the quarter ended June 30, 2025. The company reported a profit of ₹3.39 Cr for the quarter, a strong rebound from a loss of ₹(0.72) Cr in the same period last year. Revenue from operations stood at ₹34.62 Cr.

The 30th Annual General Meeting will be held on September 19, 2025, via video conferencing, with book closure from September 13-19 for voting eligibility. The Nomination & Remuneration Committee was also reconstituted, appointing Mr. Navin Kumar as Chairman. A significant operational update is the successful sale of the Madhavaram manufacturing unit assets, and the company has achieved Minimum Public Shareholding compliance.